SG11201607396WA - Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin - Google Patents
Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponinInfo
- Publication number
- SG11201607396WA SG11201607396WA SG11201607396WA SG11201607396WA SG11201607396WA SG 11201607396W A SG11201607396W A SG 11201607396WA SG 11201607396W A SG11201607396W A SG 11201607396WA SG 11201607396W A SG11201607396W A SG 11201607396WA SG 11201607396W A SG11201607396W A SG 11201607396WA
- Authority
- SG
- Singapore
- Prior art keywords
- mpla
- saponin
- monophosphoryl lipid
- liposome composition
- adjuvant formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 239000002671 adjuvant Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 title 1
- 231100000252 nontoxic Toxicity 0.000 title 1
- 230000003000 nontoxic effect Effects 0.000 title 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 title 1
- 229930182490 saponin Natural products 0.000 title 1
- 150000007949 saponins Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970118P | 2014-03-25 | 2014-03-25 | |
| PCT/US2015/022461 WO2015148648A1 (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607396WA true SG11201607396WA (en) | 2016-10-28 |
Family
ID=52829375
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808315UA SG10201808315UA (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
| SG11201607396WA SG11201607396WA (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808315UA SG10201808315UA (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10434167B2 (es) |
| EP (1) | EP3122380B1 (es) |
| JP (1) | JP6608422B2 (es) |
| KR (1) | KR102242875B1 (es) |
| CN (1) | CN107124869B (es) |
| AU (1) | AU2015236106A1 (es) |
| CA (1) | CA2943190A1 (es) |
| MX (1) | MX2016012168A (es) |
| RU (1) | RU2016141622A (es) |
| SG (2) | SG10201808315UA (es) |
| WO (1) | WO2015148648A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3015639A1 (en) * | 2016-03-09 | 2017-09-14 | Technion Research And Development Foundation Ltd. | Liposomal formulations and methods of using same in agriculture |
| JP6661454B2 (ja) * | 2016-04-21 | 2020-03-11 | 株式会社東海理化電機製作所 | 表示装置、表示板の製造方法 |
| EP3615005B1 (en) * | 2017-04-28 | 2025-07-30 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Compositions and methods for vaccine delivery |
| CN107669692B (zh) * | 2017-09-07 | 2020-09-29 | 中国人民解放军第二军医大学 | Mpla在制备电离辐射致肠道损伤防治药物中的应用 |
| AU2018330165B2 (en) * | 2017-09-08 | 2025-07-17 | Access To Advanced Health Institute | Liposomal formulations comprising saponin and methods of use |
| WO2020243166A1 (en) * | 2019-05-28 | 2020-12-03 | The Regents Of The University Of California | Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens |
| CN110613844B (zh) * | 2019-10-23 | 2024-02-27 | 中国医学科学院生物医学工程研究所 | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 |
| AU2020407871A1 (en) | 2019-12-20 | 2022-06-30 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof |
| EP3892296A1 (en) * | 2020-04-07 | 2021-10-13 | InnoMedica Holding AG | Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine |
| US20220287970A1 (en) * | 2020-06-30 | 2022-09-15 | Eyegene Inc | Composition for inhibiting saponin-induced hemolysis, containing cationic liposome |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| CN112546233A (zh) * | 2020-12-25 | 2021-03-26 | 常州大学 | 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法 |
| CN114366810B (zh) * | 2022-02-15 | 2024-11-22 | 中国人民解放军陆军军医大学 | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 |
| MX2024010416A (es) | 2022-03-14 | 2024-09-05 | Pfizer | Metodos de produccion de un adyuvante. |
| KR20250054810A (ko) | 2022-09-29 | 2025-04-23 | 화이자 인코포레이티드 | Rsv f 단백질 삼량체를 포함하는 면역원성 조성물 |
| AU2023403045A1 (en) | 2022-12-01 | 2025-06-12 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| US20240189410A1 (en) * | 2022-12-13 | 2024-06-13 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| WO2025057058A1 (en) * | 2023-09-13 | 2025-03-20 | Pfizer Inc. | Methods for producing an adjuvant |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| CN117771361B (zh) * | 2024-02-27 | 2024-06-07 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4302459A (en) | 1980-03-19 | 1981-11-24 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| CN1093255A (zh) * | 1986-06-17 | 1994-10-12 | 恩特雷麦德有限公司 | 抗甾醇疫苗 |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| US5888519A (en) | 1988-06-02 | 1999-03-30 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
| US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
| CA2138997C (en) * | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| AU5959494A (en) * | 1992-12-29 | 1994-07-19 | Entremed, Inc | Vaccines against sterols |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6846489B1 (en) * | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| ES2208946T3 (es) | 1996-08-23 | 2004-06-16 | Sequus Pharmaceuticals, Inc. | Liposomas que contienen un compuesto de cisplatino. |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| AU4907897A (en) | 1996-10-11 | 1998-05-11 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| US6120797A (en) | 1996-10-15 | 2000-09-19 | The Liposome Company, Inc. | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| CA2679765A1 (en) * | 2007-03-01 | 2008-09-12 | The Catholic University Of America | T4 bacteriophage bound to a substrate |
| GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| EP2654779B1 (en) | 2010-12-23 | 2018-02-28 | Ludwig Institute for Cancer Research, Ltd. | Liposomal formulation of nonglycosidic ceramides and uses thereof |
-
2015
- 2015-03-25 SG SG10201808315UA patent/SG10201808315UA/en unknown
- 2015-03-25 AU AU2015236106A patent/AU2015236106A1/en not_active Abandoned
- 2015-03-25 CN CN201580026334.9A patent/CN107124869B/zh active Active
- 2015-03-25 EP EP15716264.5A patent/EP3122380B1/en active Active
- 2015-03-25 WO PCT/US2015/022461 patent/WO2015148648A1/en active Application Filing
- 2015-03-25 CA CA2943190A patent/CA2943190A1/en not_active Abandoned
- 2015-03-25 MX MX2016012168A patent/MX2016012168A/es unknown
- 2015-03-25 JP JP2017502920A patent/JP6608422B2/ja active Active
- 2015-03-25 KR KR1020167026025A patent/KR102242875B1/ko active Active
- 2015-03-25 US US15/127,081 patent/US10434167B2/en active Active
- 2015-03-25 RU RU2016141622A patent/RU2016141622A/ru not_active Application Discontinuation
- 2015-03-25 SG SG11201607396WA patent/SG11201607396WA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170182152A1 (en) | 2017-06-29 |
| RU2016141622A (ru) | 2018-04-25 |
| KR102242875B1 (ko) | 2021-04-20 |
| MX2016012168A (es) | 2017-04-25 |
| CA2943190A1 (en) | 2015-10-01 |
| US10434167B2 (en) | 2019-10-08 |
| WO2015148648A1 (en) | 2015-10-01 |
| RU2016141622A3 (es) | 2018-10-26 |
| KR20170007242A (ko) | 2017-01-18 |
| EP3122380B1 (en) | 2025-03-19 |
| EP3122380A1 (en) | 2017-02-01 |
| AU2015236106A1 (en) | 2016-10-20 |
| CN107124869B (zh) | 2022-04-01 |
| JP6608422B2 (ja) | 2019-11-20 |
| JP2017515889A (ja) | 2017-06-15 |
| CN107124869A (zh) | 2017-09-01 |
| SG10201808315UA (en) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201607396WA (en) | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin | |
| ZA201805284B (en) | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same | |
| IL249671A0 (en) | Listeria-based immunogenic preparations to induce responses against tumors | |
| IL252636A0 (en) | A bromodomain inhibitor as an adjuvant for cancer immunotherapy | |
| IL251098A0 (en) | Multi-leaf bubble compounds and methods of use | |
| EP3377099A4 (en) | ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE | |
| EP3273950A4 (en) | ADJUVANE COMPOSITIONS AND RELATED METHODS | |
| EP2825196A4 (en) | ADJUVANT AND VACCINE COMPOSITIONS | |
| EP3118204A4 (en) | O-phenyl chalcone compound and preparation method and use thereof | |
| ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
| EP3131579A4 (en) | Vaccine adjuvant compositions | |
| HK1259146A1 (zh) | 用於流感疫苗接種的方法和組合物 | |
| IL247159B (en) | Components of pcsk9 | |
| EP3137111A4 (en) | Compositions and methods for intradermal vaccine delivery | |
| EP3097911B8 (en) | Metabolism-improving agent comprising rare fatty acid | |
| GB201704417D0 (en) | Improved li vaccine adjuvant | |
| PL3223846T3 (pl) | Kompozycje adiuwantowe i powiązane sposoby | |
| ZA201802565B (en) | New adjuvant and vaccine composition containing the same | |
| ZA201800285B (en) | Liposomal adjuvant compositions | |
| EP3538197A4 (en) | DEVICES AND METHODS FOR IMPROVING IMMUNOGENICITY TO INTRADERMAL VACCINATION | |
| EP3135292A4 (en) | Antiobesity agent containing walnut extract | |
| HK40098029A (en) | Adjuvant and vaccine compositions | |
| EP3271024A4 (en) | Isg15 and its use as an adjuvant | |
| AU2014902031A0 (en) | Immunogenic vaccines and uses thereof | |
| HK1238148A1 (en) | Listeria-based immunogenic compositions for eliciting anti-tumor responses |